Abstract
Five metabolites of the antimalarial piperaquine (PQ) (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane) have been identified and their molecular structures characterized. After a p.o. dose of dihydroartemisinin-piperaquine, urine collected over 16 h from two healthy subjects was analyzed using liquid chromatography (LC)/UV, LC/tandem mass spectrometry (MS/MS), Fourier transform ion cyclotron resonance (FTICR)/MS, and H NMR. Five different peaks were recognized as possible metabolites [M1, 320 m/z; M2, M3, and M4, 551 m/z (PQ + 16 m/z); and M5, 567 m/z (PQ + 32 m/z)] using LC/MS/MS with gradient elution. The proposed carboxylic M1 has a theoretical monoisotopic molecular mass of 320.1166 m/z, which is in accordance with the FTICR/MS (320.1168 m/z) findings. The LC/MS/MS results also showed a 551 m/z metabolite (M2) with a distinct difference both in polarity and fragmentation pattern compared with PQ, 7-hydroxypiperaquine, and the other 551 m/z metabolites. We suggest that this is caused by N-oxidation of PQ. The results showed two metabolites (M3 and M4) with a molecular ion at 551 m/z and similar fragmentation pattern as both PQ and 7-hydroxypiperaquine; therefore, they are likely to be hydroxylated PQ metabolites. The molecular structures of M1 and M2 were also confirmed using H NMR. Urinary excretion rate in one subject suggested a terminal elimination half-life of about 53 days for M1. Assuming formation rate-limiting kinetics, this would support recent findings that the terminal elimination half-life of PQ has been underestimated previously.
Footnotes
-
This study was part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme Thailand (077166/Z/05/Z) supported by the Wellcome Trust of Great Britain. We thank the Medicines for Malaria Venture and the Swedish International Development Cooperation Agency (SIDA) for economic support. The support by the Swedish Strategic Foundation (SSF), Swedish Research Council (621-2002-5261, 629-2002-6821), and Applied Biosystems/MDS Sciex is acknowledged.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.106.011494.
-
ABBREVIATIONS: PQ, piperaquine (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane); DHA, dihydroartemisinin; CQ, chloroquine; 7-OHPQ, 7-hydroxypiperaquine; LC, liquid chromatography; MS/MS, tandem mass spectrometry; FTICR, Fourier transform ion cyclotron resonance; SPE, solid-phase extraction; M1, metabolite 1; M2, metabolite 2; M3, metabolite 3; M4, metabolite 4; M5, metabolite 5; P450, cytochrome P450; MAO, monoamine oxidase.
- Received June 14, 2006.
- Accepted August 30, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|